<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983045</url>
  </required_header>
  <id_info>
    <org_study_id>16-214-02</org_study_id>
    <nct_id>NCT02983045</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 )</brief_title>
  <acronym>PIVOT-02</acronym>
  <official_title>A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this four-part study, NKTR-214 will be administered in combination with nivolumab in Part
      1, in combination with nivolumab with or without various chemotherapies in Part 2, and with
      nivolumab and ipilimumab in Parts 3 &amp; 4. In Part 1, the Recommended Phase 2 Dose (RP2D) of
      NKTR-214 in combination with nivolumab will be determined. In Part 2, NKTR-214 with nivolumab
      at the RP2D will be evaluated as first-line therapy and/or as second or third line therapy in
      select patients with Melanoma, Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer
      (NSCLC), Urothelial Carcinoma (UC), metastatic Breast Cancer (mBC) and Colorectal Cancer
      (CRC). In addition, in Part 2, the RP2D of NKTR-214 with nivolumab and various chemotherapies
      and regimens in select cohorts of NSCLC patients will be determined. In Part 3, several
      different regimens of the triplet combination of NKTR-214 plus nivolumab and ipilimumab will
      be evaluated in select patients with RCC, NSCLC, Melanoma, and UC. In Part 4, the safety and
      efficacy of the triplet combination will be evaluated further in select patients with RCC,
      NSCLC, Melanoma and UC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NKTR-214 (investigational agent) is an IL-2 pathway agonist designed to target CD122, a
      protein which is found on certain immune cells (known as CD8+ T Cells and Natural Killer
      Cells) to expand these cells to promote their anti-tumor effects. Nivolumab is a full human
      monoclonal antibody that binds to PD-1 (programmed cell death protein 1) on immune cells and
      promotes anti-tumor effects. NKTR-214, nivolumab and ipilimumab each target the immune system
      differently and may act synergistically to promote anti-cancer effects.

      The study is designed in four parts.

      Part 1: Dose escalation of NKTR-214 in combination with nivolumab. Part 1 has been completed
      and the recommended phase 2 dose (RP2D) has been identified, which is being studied further
      in Parts 2, 3 and 4 of the study.

      Part 2: Dose expansion of NKTR-214 in combination with nivolumab. Patients with the following
      tumor types (Melanoma, RCC, NSCLC, UC, mBC and CRC) will be enrolled to receive the RP2D of
      NKTR-214 in combination with nivolumab. In addition, NKTR-214 with nivolumab and other
      anti-cancer therapies including cytotoxic chemotherapy will be evaluated in select patients
      with NSCLC. Each cohort in Part 2 has a target enrollment of 12-36 patients and could include
      up to a total of 650 patients who are either checkpoint-therapy naïve or anti-PD-1 or
      anti-PD-L1 relapsed/refractory. One dedicated and separate cohort in Part 2 will evaluate
      NKTR-214 with nivolumab in an additional 100 second-line NSCLC patients previously treated
      with an anti-PD-1 or anti-PD-L1 in combination with doublet platinum-containing cytotoxic
      chemotherapy in first-line.

      Part 3: Schedule and safety finding of NKTR-214 in combination with nivolumab and ipilimumab.
      During this part of the study, the RP2D triplet combination schedules will be determined in
      the following tumor types: RCC, NSCLC, Melanoma, or UC.

      Part 4: Dose expansion of triplet combinations of NKTR-214 in combination with nivolumab and
      ipilimumab in select tumor types. Each cohort will enroll between 6-36 patients and could
      include up to 106 patients. Enrollment into Part 4 will commence once the RP2D for the
      triplet combination has been established in Part 3 for each respective tumor type.

      All patients enrolled in the study will be closely monitored for safety, tolerability and
      response per RECIST criteria. The primary efficacy endpoint of the combination will be
      assessed using objective response rate (ORR). Exploratory immunological biomarkers in plasma
      and tumor samples will evaluate immune activation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of NKTR-214 in combination with nivolumab as assessed by the Objective Response Rate (ORR) based on immune-related RECIST (irRECIST) at the RP2D.</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of NKTR-214 in combination with nivolumab and ipilimumab as assessed by the Objective Response Rate (ORR) based on immune-related RECIST (irRECIST) at the RP2D.</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Within 3 years from study start</time_frame>
    <description>Overall survival is defined as the time from date of first dose to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the date of the first objectively documented tumor progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Within 3 years from study start</time_frame>
    <description>CBR will be assessed as the number of subjects with a BOR of Complete Response (CR), confirmed Partial Response (PR), or Stable Disease (SD) (where the duration of SD should be ≥ 84 days) divided by the total number of subjects in the Response Evaluable Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>DOR is defined as time between the date of first radiographic images that documented objective response and the date of the first radiographic images that documented disease progression.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">557</enrollment>
  <condition>Melanoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Combination of NKTR-214 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKTR-214 in escalating doses will be combined with one of the two proposed doses of nivolumab. The goal of this dose escalation Part 1 of the study is to find the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Combination of NKTR-214 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NKTR-214+nivolumab in combination with cytotoxic chemotherapies for the following 2 cohorts of the Part 2:
NSCLC 1L nonsquamous plus platinum/pemetrexed NSCLC 1L squamous plus platinum/taxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Combination of NKTR-214 + nivolumab + ipi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKTR-214 will be combined with nivolumab and ipilimumab. The goal of this dose schedule finding part of the study is to define the RP2D and administration schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion of the Part 3 RP2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Combination of NKTR-214 + nivolumab + ipilimumab that may enroll between 12-26 patients per tumor type</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of NKTR-214 + nivolumab</intervention_name>
    <description>Patients with select tumor types will receive NKTR-214 doses administered either q3w or q2w, in combination with 240 mg nivolumab q2w or in combination with 360 mg of nivolumab q3w.</description>
    <arm_group_label>Dose Escalation: Combination of NKTR-214 + nivolumab</arm_group_label>
    <other_name>NKTR-214 + Opdivo®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of NKTR-214 + nivolumab</intervention_name>
    <description>Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.</description>
    <arm_group_label>Dose Expansion: Combination of NKTR-214 + nivolumab</arm_group_label>
    <other_name>NKTR-214 + Opdivo®</other_name>
    <other_name>Carboplatin (Paraplatin®)</other_name>
    <other_name>Cisplatin (Platinol®)</other_name>
    <other_name>Pemetrexed (Alimta®)</other_name>
    <other_name>Paclitaxel (Taxol®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of NKTR-214 + nivolumab + ipilimumab</intervention_name>
    <description>Combination of NKTR-214 at 0.006 mg/kg q3w in combination with nivolumab and ipilimumab in up to three different dosing schedules to identify dose and schedules that will proceed into Part 4.</description>
    <arm_group_label>Experimental: Combination of NKTR-214 + nivolumab + ipi</arm_group_label>
    <other_name>NKTR-214 + Opdivo® + Yervoy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of NKTR-214 + nivolumab + ipilimumab</intervention_name>
    <description>Combination of NKTR-214 + nivolumab + ipilimumab will be administered at the RP2D dose/schedule in patient cohorts with select tumor types.</description>
    <arm_group_label>Dose Expansion of the Part 3 RP2D</arm_group_label>
    <other_name>NKTR-214 + Opdivo® + Yervoy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA - For Parts 1-4:

          -  Histologically confirmed diagnosis of a locally advanced (not amenable to curative
             therapy such as surgical resection) or metastatic solid tumors

          -  Life expectancy &gt; 12 weeks

          -  Patients must not have received prior interleukin-2 (IL-2) therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Measurable disease per RECIST 1.1

          -  Patients with stable brain metastases under certain criteria

          -  Fresh and archival tumor tissue available Tumor specific inclusion criteria may apply.

        EXCLUSION CRITERIA - For Parts 1-4:

          -  Use of an investigational agent or an investigational device within 28 days before
             administration of first dose of NKTR--214

          -  Females who are pregnant or breastfeeding

          -  Participants who have an active autoimmune disease requiring systemic treatment within
             the past 3 months or have a documented history of clinically severe autoimmune disease
             that requires systemic steroids or immunosuppressive agents

          -  History of organ transplant that requires use of immune suppressive agents

          -  Active malignancy not related to the current diagnosed malignancy

          -  Evidence of clinically significant interstitial lung disease or active, noninfectious
             pneumonitis

          -  Participants who have had &lt; 28 days since the last chemotherapy, biological therapy,
             or &lt; 14 days from approved tyrosine kinase inhibitor (TKI) therapy, or systemic or
             inhaled steroid therapy at doses greater than 10mg of prednisone Tumor specific
             exclusion criteria may apply.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika Puente, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution - La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution- Palo Alto</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Maywood</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - New York 1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - New York 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Fairfax ISC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Fairfax VCS</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Edegem</name>
      <address>
        <city>Edegem</city>
        <zip>02650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <zip>08500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Liège</name>
      <address>
        <city>Liège</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Wilrijk</name>
      <address>
        <city>Wilrijk</city>
        <zip>02610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Toronto SBH</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Toronto PMH</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M10</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Marseille LPC</name>
      <address>
        <city>Marseille</city>
        <state>Brouches-duRhone</state>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Saint-Herblain</name>
      <address>
        <city>Saint-Herblain</city>
        <state>Loire-Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Marseille HN</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Villejuif Cedex</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Milano FIIN</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Milano 2</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Roma</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Buriasco (Turin)</name>
      <address>
        <city>Turin</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Brzozów</name>
      <address>
        <city>Brzozów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Kraków</name>
      <address>
        <city>Kraków</city>
        <zip>31115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Otwock</name>
      <address>
        <city>Otwock</city>
        <zip>05400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Poznań WCPT</name>
      <address>
        <city>Poznań</city>
        <zip>60569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Poznań MPS</name>
      <address>
        <city>Poznań</city>
        <zip>60693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Lodz</name>
      <address>
        <city>Łódź</city>
        <zip>93509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Barcelona HQB</name>
      <address>
        <city>Barcelona</city>
        <zip>8023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Barcelona HCB</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Madrid HURCPO</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Madrid HU12</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Madrid CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Pamplona</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - West Yorkshire (Bradford)</name>
      <address>
        <city>Leeds</city>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - London</name>
      <address>
        <city>London</city>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Northwood</name>
      <address>
        <city>Northwood</city>
        <zip>HA62RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - Withington</name>
      <address>
        <city>Withington</city>
        <zip>M204BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NKTR-214</keyword>
  <keyword>Bempegaldesleukin</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Advanced</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>anti-CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

